requip depot 2 mg depottabletti
glaxosmithkline oy - ropinirole hydrochloride - depottabletti - 2 mg - ropiniroli
requip depot 4 mg depottabletti
glaxosmithkline oy - ropinirole hydrochloride - depottabletti - 4 mg - ropiniroli
requip depot 8 mg depottabletti
glaxosmithkline oy - ropinirole hydrochloride - depottabletti - 8 mg - ropiniroli
ropinirol krka 2 mg depottabletti
krka sverige ab - ropinirole hydrochloride - depottabletti - 2 mg - ropiniroli
ropinirol krka 4 mg depottabletti
krka sverige ab - ropinirole hydrochloride - depottabletti - 4 mg - ropiniroli
ropinirol krka 8 mg depottabletti
krka sverige ab - ropinirole hydrochloride - depottabletti - 8 mg - ropiniroli
ropinirol sandoz 2 mg depottabletti
sandoz a/s sandoz a/s - ropiniroli hydrochloridum - depottabletti - 2 mg - ropiniroli
ropinirol sandoz 4 mg depottabletti
sandoz a/s sandoz a/s - ropiniroli hydrochloridum - depottabletti - 4 mg - ropiniroli
ropinirol sandoz 8 mg depottabletti
sandoz a/s sandoz a/s - ropiniroli hydrochloridum - depottabletti - 8 mg - ropiniroli
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - muut hermoston huumeet - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.